Released : 10/01/2018 16:31
RNS Number : 5295B
Evgen Pharma PLC
10 January 2018
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuer | Evgen Pharma PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | X | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to the | Seneca Partners Limited | |||
4. Full name of shareholder(s) (if different from 3.): | Share Nominees Limited WCS Nominees Limited | |||
5. Date of the transaction and date on | 2 January 2018 | |||
6. Date on which issuer notified: | 10 January 2018 | |||
7. Threshold(s) that is/are crossed or | 5% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type of
if possible using |
Situation previous | Resulting situation after the triggering transaction | ||||||||||||||
Number |
Number |
Number |
Number of voting | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
3,536,022 | 3,536,022 | 6,872,726 | 6,872,726 | 7.37% | ||||||||||||
GB00BSVYN304 | ||||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial | Exercise price | Expiration date |
Exercise/ | Number of voting rights instrument refers to | % of voting rights | |||||||||||
Nominal | Delta | |||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
6,872,726 | 7.37% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the | ||
Proxy Voting: | ||
10. Name of the proxy holder: | ||
11. Number of voting rights proxy holder will cease | ||
12. Date on which proxy holder will cease to hold | ||
13. Additional information: | ||
14. Contact name: | Seneca Partners Limited | |
15. Contact telephone number: | 01942 271 746 | |
This information is provided by RNS
The company news service from the London Stock Exchange
ENDHOLBLGDBLDBBGIG
Evgen Pharma plc published this content on 10 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 January 2018 16:44:08 UTC.
Original documenthttp://otp.investis.com/clients/uk/evgen_pharma/rns/regulatory-story.aspx?cid=1240&newsid=965452
Public permalinkhttp://www.publicnow.com/view/673EEFC9545C7BFA2475FF25A2D3D9CF08286D9B